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Abstract
Background.CRIM1isaplasmamembraneboundprotein
containing six cysteine-rich repeats (CRR). Through these,
CRIM1 has been shown to interact with a subgroup of the
TGF-β superfamily, the bone morphogenic proteins (BMP)
isoforms 2, 4 and 7. The probable action is to modulate
the signalling properties of these factors. CRIM1 has also
been shown to regulate the release of VEGFA by podocytes
duringrenalorganogenesis.Knock-outstudiesinmicehave
shownthatCRIM1iscriticallyinvolvedinthedevelopment
ofthecentralnervoussystem,eyeandkidney.Replacement
ofCRIM1withadefectiveversionleadstorenaldysgenesis
and perinatal death. We have analysed the distribution of
CRIM1 in adult human renal tissue.
Methods. To this end, we have used immunofluorescence,
immunohistochemistry and immunoelectron microscopy.
We performed western blotting for the CRIM1 protein,
using lysates from isolated glomerular podocytes and hu-
man renal tissue homogenate. By using quantitative PCR,
we compared the CRIM1 mRNA levels in podocytes, hu-
man renal tissue homogenate, primary human renal proxi-
mal tubular epithelial cells and primary human pulmonary
artery smooth muscle cells.
Results. The results show that in the human adult kidney,
CRIM1 is mainly expressed in the glomerular podocytes
andisassociatedwiththeinsertionalregionofthefiltration
slit diaphragm (SD) of the podocyte pedicles.
Conclusions. CRIM1 is a protein that should be added to
the list of proteins associated with the podocyte filtration
SD and with the probable action of modulating BMP and
VEGFA signalling.
Keywords: bone morphogenic protein; filtration slit membrane;
immunoelectron microscopy; podocyte
Introduction
CRIM1 is an N-glycosylated plasma membrane bound pro-
tein with a large extracellular moiety containing six von
Willebrand-like, cysteine-rich repeats (CRR) and an IGF-
binding protein motif. It has been proposed that a minor
proportion of CRIM1 also appears as a cleaved extracellu-
lar molecule [1,2]. In the adult human, CRIM1 mRNA has
been detected in several organs, although the highest levels
were seen in the placenta, followed by the kidney [1].
The biological significance of CRIM1 during develop-
ment has been firmly established. Studies conducted in
zebrafish show aberrant development of the somites and
vasculartissueswhenCRIM1wasknockeddown[3].Stud-
ies in mice have demonstrated the importance of CRIM1
for the development of the eye, the central nervous system
and the kidney [4–6].
In the developing kidney, the presence of CRIM1 was
detected by in situ hybridization, as early as during the
metanephricstagewhereexpressionwasseenintheureteric
bud, the early condensing mesenchyme and the comma
shaped bodies [7]. By creating a gene-trap mouse line,
where a truncated hypomorph of CRIM1 was allowed to be
developmentally expressed, it was shown that the transgene
was expressed in the glomerular epithelial cells, podocytes,
mesangial cells, urothelium and vascular pericytes of the
arterial vasculature [4,5].
Functionally, it was demonstrated that the bi-allelic form
of the hypomorph CRIM1 resulted in perinatal death due
to multiple organ defects and renal dysgenesis. The most
pronounced disturbance was seen in the glomerulus, which
demonstrated mesangiolysis, podocyte foot process efface-
ment and dilation of the capillary loops. CRIM1 has also
been implicated in angiogenesis, since it is required for the
tube formation of capillary endothelial cells in vitro and is
expressed in the endothelial lining of blood vessels in vivo
[8].
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The structure of CRIM1 makes it similar to other devel-
opmentally important proteins, such as vertebrate chordin
and gremlin, the short gastrulation protein (sog) and kielin
of Drosophila and uterine sensitization associated gene-1
(USAG-1) [9–13]. These are known to interact via their
CRR domains with members of the TGF-β superfamily,
more specifically the bone morphogenic proteins (BMP).
In the mammalian kidney, the TGF-β superfamily plays a
central role in disease as well as during renal development.
TGF-β is generally regarded as the main profibrogenic
agent, mediating the interstitial and glomerular fibrosis,
which is the common final endpoint of most chronical re-
nal diseases [14].
The BMP family has a crucial role in renal develop-
ment and renal function postnatally. The BMP isoforms
2–7 are directly involved in the development of the kidney.
Knock-out studies in mice demonstrated early embryonic
lethality (BMP 2, 4 knock-out) or postnatal death (BMP
7 knock-out). All phenotypes showed a pronounced renal
dysgenesis. No renal abnormality was detected if BMP3
and 6 were inactivated.
Much focus has been devoted to the isoform BMP7. In
several experimental animal models of acute and chronic
renal disease, BMP7 has been shown to reduce the inflam-
matory and fibrogenic processes that would otherwise lead
to renal damage [15,16].
It has been convincingly shown in COS-1 cells that
CRIM1 interacts with the pre-protein forms of BMP2, 4
and 7, tethering the inactive proforms of these factors to
theextracellularfaceoftheplasmamembrane[2].Whether
this is the general mode of action by CRIM1 in other cell
types, such as in the placenta or kidney, still remains to
be elucidated. Little is known regarding the expression of
known CRIM1 ligands in the human adult kidney. BMP7
has been localized mainly to the distal nephron, BMP2 ex-
pressionhasbeensaidtobedownregulatedinadultkidneys
and data are lacking as to the distribution of BMP4 [17,18].
It has also been shown that CRIM1 is able to interact with
VEGFA, suggesting that CRIM1 modulates the delivery of
VEGFA from the podocytes to the glomerular endothelial
cells, thus regulating the release of this growth factor from
the site of production [5]. The podocytes and glomerular
endothelial cells are among the few cell types that continu-
ously express VEGFA throughout life [19].
The exact localization of CRIM1 in the adult human
kidney is still unknown. To this end we analysed human
renal tissues for the presence of CRIM1, using a combina-
tion of immunohistochemical techniques, and the compar-
ison of the expressional levels of CRIM1 mRNA in human
glomerular podocytes, renal tissue homogenate, primary
humanrenalproximaltubularcellsandprimaryhumanpul-
monary artery smooth muscle cells. We also compared the
protein levels of CRIM1 in protein lysates from podocytes
and human renal homogenate.
Materials and methods
Cell culture
A conditionally immortalized human podocyte cell line was obtained, the
characteristics of which have been described in detail elsewhere [20]. In
brief, isolated podocytes have been transfected with the catalytic sub-
unit of the human telomerase gene and a temperature-sensitive mutant of
the SV-40 large T-antigen. At the ‘permissive’ temperature of 33◦C, the
podocytesproliferaterapidly,drivenbytheSV-40T-antigen.Asubsequent
thermoswitchto37◦CinactivatestheT-antigenandinsteadinducesgrowth
arrest and differentiation of the podocytes, which express marker genes of
differentiated podocytes such as synaptopodin, α-actinin-4 and CD2AP.
The cells were grown in RPMI 1640 (Sigma, St Louis, MO, USA) with
10% fetal calf serum and addition of insulin-transferrin-selenium 100×
stocksolution(InvitrogenInc,Carlsbad,CA,USA)toafinalconcentration
of 1×. After 16 days at 37◦C, the cells were harvested for standard protein
extraction.Primaryhumanrenalproximaltubularcells(RPTEC)wereob-
tained from Cambrex Bio Science (Walkersville MD, USA). The primary
human pulmonary artery smooth muscle cells (HPASMC) were obtained
from ScienceCell Research Laboratories (San Diego, CA, USA). Both
cell systems were cultured according to the instructions of the respective
manufacturers.
Immunohistochemistry
Sections of formalin fixed and paraffin embedded renal tissue, thickness
4 µm, were deparaffinized using xylene and graded ethanol for rehy-
dration according to standard protocols. Human placenta was included
as an additional positive control. Antigen retrieval was performed by
boiling in a 10 mM citrate buffer, pH 6. The tissue sections were in-
cubated by two separate antisera to CRIM1, one produced in chicken
(Human Proteome Resource, HPR www.hpr.se /Kind gift from Pro-
fessor Carl Borreb¨ ack, Lund University) and one from rabbit origin
(Atlas antibodies, Stockholm, Sweden). Also CRIM1 antibodies from
Santa Cruz (sc-73860, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and R & D systems (MAB1917, R & D systems, Abingdon, UK) were
evaluated for immunohistochemistry, although the latter two sera had
not been primarily developed for immunohistochemistry. Staining was
detected using the Envision system and DAKO TechMate 500 staining
equipment, according to the instructions of the manufacturer (DAKO,
Copenhagen, Denmark). For nuclear counterstaining haematoxylin was
used. As negative control, the primary antibody was omitted. Ethical per-
mission was obtained from the Ethics Committee at Lund University
(LU 289-07).
Immunofluorescence
Renal tissue was embedded in Tissue Tek cryo mountant (Sakura Finetek,
Tokyo, Japan). Sections of 8 µm thickness were cut and allowed to dry
overnight. The sections were fixed for 5 min in methanol having a temper-
ature of −20◦C. After blocking with 3% BSA in 10 mM PBS, the sections
were incubated with a primary rabbit antibody against CRIM1 overnight
at 8◦C, at a dilution of 1:200 (Atlas antibodies). Following washing, a sec-
ondary goat anti rabbit antibody was applied at a dilution of 1:200 (Alexa
fluor 488 goat anti rabbit, Invitrogen).
Immunoelectron microscopy (iEM)
Tissues used for immunoelectron microscopy (iEM) were fixed in 1%
paraformaldehyde and 0.5% glutaraldehyde (GA), in a 0.1 M phosphate
buffer. The tissues were dehydrated with methanol and embedded
in Lowicryl K11M (Chemische Werke Lowi GmbH, Waldkraiburg,
Germany) as described elsewhere [21]. The specimens were cut into
ultrathin sections (60 nm) with a diamond knife and mounted on
carbon/formvar nickel grids. To minimize non-specific labelling, grids
were incubated in 2% bovine serum albumin (BSA, fraction IV) and 2%
gelatin in a 0.1 M phosphate buffer at pH 7.4 for 2 h at room temperature
followed by incubation overnight with anti-CRIM1 antibodies, diluted 1:
20 in a buffer containing 0.1% BSA and 0.1% gelatin (Atlas antibodies).
After rinsing, the sections were incubated with protein A conjugated with
10 nm colloidal gold (Amersham Pharmacia Biotech, Little Chalfont,
England) diluted 1:100 in the same buffer as for a primary antibody for
2 h at room temperature. The grids were then rinsed in a 0.1 M phosphate
buffer and post-fixation was performed in 2% GA in a 0.1 M phosphate
buffer for 20 min. The specimens were contrasted with 4% uranyl acetate
followed by Reynold’s lead citrate. The sections were examined in a LEO
906 transmission microscope(LEO Electron Microscopy Ltd,Cambridge,
England) at 80 kV , and digital images were taken using a Morada camera
(Soft Imaging System, GmbH, M¨ unster, Germany). The number of
gold particles over different compartments, i.e. podocytes, glomerular
basement membrane (GBM), endothelial cells and mesangial matrix were2040 J. Nystr¨ om et al.
Table 1. Sequences of the DNA primers used in real-time quantitative
PCR experiments
Gene Forward (5 -3 )R e v e r s e ( 5  -3 )
CRIM1 TGCTATGGAGAA GGCCAGTGAGC
GGGTATTCCTTT AAATTGAAAA
SDHA TGGGAACAA CCACCACTGCA
GAGGGCCATCTG TCAAATTCATG
YWHAZ ACTTTTGGTACA CCGCCAGGAGG
TTGTGGCTTCAA ACAAACCAGTAT
UBC ATTTGGGTC TGCCTTGACA
GCGGTTCTTG TTCTCGATGGT
counted on printed images. The area in podocyte was limited by drawing
a line parallel with the GBM and 2 µm into the podocyte [22]. The area of
different compartments was calculated using point counting using 1 and
2cmsquarelatticesaccordingtoWeibel[23].Apilotstudywasperformed
to determine the number of pictures needed for an appropriate sample
using cumulative mean plot for evaluation. Thus, 20 different images
representing the capillary loop and 5 images representing mesangium
matrix were collected.
Real-time quantitative PCR (Q-PCR)
The relative gene expression levels of CRIM1 in two individual cultures
of immortalized podocytes were compared to the expressional levels of
CRIM1 in whole kidney RNA from two human kidneys, HPASMC and
RPTEC. This was performed by use of real-time quantitative PCR (Q-
PCR) based on two-step SYBR green I chemistry.
Total RNA was extracted from cells or renal tissue using TRI-
zol reagent (Invitrogen) according to the manufacturer’s instructions.
Samples of 2 µg were subjected to DNase treatment and washed.
Synthesis of cDNA was performed using random hexamers and Su-
perscript II RT enzyme according to the manufacturer’s instructions
(Invitrogen). The resulting cDNA was used as a template in Q-
PCR reactions using SYBR green Master Mix (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s recommendations.
The amplifications were run on a Gene Amp 7300 Sequence detector
(Applied Biosystems), using two temperature cyclings (10 min 95◦C, 40
cycles of 95◦C for 15 s and 60◦C for 60 s). Real-time detection of the
PCR product was performed using the SYBR green master mix (Applied
Biosystems), and all reactions were performed in triplicates. For relative
quantification of mRNA expressional levels, we used the comparative CT
method and data were normalized to the expression of three reference
genes (SDHA, YWHAZ and UBC) [24]. All Q-PCR primers were de-
signed using the Primer Express software from Applied Biosystems. The
sequences for the PCR primers used are given in Table 1.
Western blot analysis
TheproteinconcentrationsweredeterminedbyusingtheBCAProteinAs-
say Reagent kit (Pierce, Rockford, IL, USA). For western blotting, 20 µg
of protein was separated on a 12% SDS-PAGE and transferred to Hy-
bond ECL nitrocellulose membranes (Amersham Biosciences, Little
Chalfont, UK). The membranes were incubated with primary anti-
human CRIM-1 1:200 (R & D systems, Abingdon, UK) or anti GAPDH
1:2000 (Chemicon-Millipore, Nodinge, Sweden) antibodies followed by
peroxidase-conjugated anti-mouse 1:5000 (Amersham Biosciences) an-
tibody. The proteins were detected using enhanced chemiluminescence
detection system (ECL+ plus) reagent (Amersham Biosciences) accord-
ing to the manufacturer’s instructions and exposed on ECL Hyper Film
(Amersham Biosciences).
Results
Immunohistochemistry
The results of immunohistochemistry using the CRIM1 an-
tiserumfromAtlasantibodiesperformedonformalin-fixed
Fig. 1. (A) Section of formalin fixed normal human kidney stained with a
rabbit polyclonal antibody directed against CRIM1 at a dilution of 1:200.
Magnification200×.(B)Controlsection,wheretheprimaryantibodywas
omitted and replaced by preimmune serum. Magnification 200×. Scale
barrepresents50µm.(C)ImmunofluorescencestainingpatternofCRIM1
in a glomerulus from fresh frozen human renal tissue stained with a rabbit
polyclonal antibody against CRIM1, at a dilution of 1:100, showing a
granular serpentine staining pattern indicative of antigens with podocyte
or glomerular basal membrane origin. Nuclei have been counterstained by
useofDAPI.Magnification500×.(D)Controlsection,wheretheprimary
antibody as well as DAPI was omitted and replaced by preimmune serum
and Vectashield mounting medium only. Magnification 500×. Scale bar
represents 40 µm.
and paraffin-embedded renal tissue is shown in Figure 1A.
Linear staining can be seen in a pattern that is typical for
either the glomerular basal membrane, the podocyte pedi-
clesortobothofthesestructures.Themesangialareaswere
negative with respect to staining as well as the tubular, in-
terstitial and vascular compartments of the kidney. Also,
the chicken antibody from HPR worked well and resulted
in similar staining patterns. The sera from Santa Cruz and
R & D systems failed to produce a signal in renal tissue and
also in human placenta that was used as a positive control
(data not shown).
Immunofluorescence
The results of immunofluorescence of fresh frozen and
methanolfixedtissuescanbeseeninFigure1C.Itbasically
shows a similar staining pattern, but with the additional in-
formation that the basal membrane staining is rough and
granular in a serpentine fashion. This staining pattern is
typical for antigens residing in or close to the glomerularCRIM1 in filtration slit of podocytes 2041
Fig.2. Electronmicrographsfromthreeindividualhumankidneys(A–C),
fixed with a reduced percentage of glutaraldehyde, showing the transected
podocyte foot processes (f), the glomerular basal membrane (GBM) and
the glomerular endothelium (e). Following incubation with a rabbit anti-
CRIM1 antibody, immunolabelling was performed by incubation with
10 nm goldspheres conjugated to protein A. The majority (85%) of
the spheres (arrows) were localized to the plasma membrane of the
podocyte foot processes at a characteristic distance from the GBM,
where the glomerular filtration slit membrane is localized. Magnification
70 000×.
basal membrane, as in the podocyte processes. The nega-
tive controls showed no staining in either of the settings,
Figures 1B and 1D.
Immunoelectron microscopy
Several human kidney samples were analysed by electron
microscopy following fixation in reduced amount of glu-
taraldehyde, showing similar results. Three of these are
shown in Figure 2. In these, a total of 11 310 nm gold
spheres were counted. Of these, 96 spheres (85%) were
localized to the podocytes. The majority of the podocyte
staining (65%, 63 spheres) was localized to the plasma
membrane, more specifically to the filtration slit area of
the podocyte pedicles. The remaining signal localized to
the podocytes was not plasma membrane associated; in-
stead, it was seen in the cytoplasmic compartment of the
cell body of the podocyte. The distribution of the re-
maining labelling signal was as follows: glomerular basal
membrane four spheres (3.5%), the glomerular endothe-
lial cell five spheres (4.4%) and the cytoplasmic part
of the mesangial cell eight spheres (7.1%). The tubular
and interstitial compartments were negative and no stain-
ing was seen in the extraglomerular vasculature (data not
shown).
Fig.3. Resultsfromreal-timequantitativeRT-PCRassessmentofCRIM1
mRNA levels in two separate cultures of conditionally immortalized
podocytes (Podocytes 1 and 2), normal human kidney samples (Normal
1 and 2), primary human renal proximal tubule cells (RPTEC 1 and 2)
and primary human pulmonary artery smooth muscle cells (HPASMC 1
and 2). Results are in arbitrary units ± SD. The levels were normalized
to three separate housekeeping genes and the identity of the PCR product
was confirmed by sequencing.
Human podocyte cell culture
The cells were of podocyte origin as judged by light mi-
croscopy, by initial characterization [20], and by positive
PCR for synaptopodin, α-actinin-4, and CD2AP (data not
shown).
Quantitative analysis by Q-PCR
The CRIM1 mRNA levels in immortalized human
podocytes were quantitatively assessed compared to the
mRNAlevelsfromtwohumankidneys,primaryrenalprox-
imal tubular cells and primary human pulmonary artery
smooth muscle cells. The transcriptional levels were nor-
malized to three separate house keeping genes, and the
results indicate that the levels were ∼8- to 10-fold higher
in the podocytes, as compared to normal kidney and 3-fold
higher as compared to RPTECs. The levels in HPASMC
were similar to those of the immortalized podocytes
(Figure3).ThecorrectidentityoftheresultingPCRproduct
was confirmed by sequencing.
Protein expression analysis by western blotting
The protein levels of CRIM1 in cultured podocytes dur-
ing the proliferative phase and differentiation phase were
similar and ∼10-fold higher than the levels of the CRIM1
protein in whole renal tissue homogenate (Figure 4).
Discussion
Proteins expressed by podocytes can be assigned to three
compartments: the apical, meaning the podocyte above the
plane of the slit diaphragm (SD), the basal compartment
representing the part of the podocyte pedicle that is an-
chored to and in direct contact with the GBM and finally,
the SD domain, meaning the SD proteins and the proteins
associated with its insertion to the actin cytoskeleton of the
foot process.
Based on animal model systems, CRIM1 seems to af-
fect several key processes during development, particularly2042 J. Nystr¨ om et al.
Fig. 4. Western blot analysis of CRIM1 expression in immortalized
podocytes during the proliferative phase and differentiated phase as com-
paredtotheexpressioninrenaltissuehomogenate.Normalizationhasbeen
performed by detecting for GAPDH. The protein levels in the podocytes
is approximately ten times higher than the levels in tissue homogenate.
in the developing kidneys. A further important feature
of CRIM1-disrupted mice was that proteinuria and foot-
process effacement were shown to be combined with a
reduction of phospho-Smad 1/5/8 levels in the mature
glomerulus [5]. Phospho-Smad 1/5/8 are the downstream
effectors of BMP, which indicates that the glomerular dam-
age seen during CRIM1 disruption is at least partly due
to a reduction of BMP signal transduction. Foot-process
effacement and proteinuria are hallmarks of podocyte dam-
age and indirectly; these findings implicate an ongoing
CRIM1/BMP signalling activity in the mature podocyte,
where CRIM1 may be essential for maintaining the BMP
signalling intensity, the reduction of which may lead to foot
process effacement and proteinuria.
This is, to our knowledge, the first study showing that
the plasma membrane protein CRIM1 is localized mainly
to the podocytes of the adult human kidney. Using both im-
munofluorescence and immunohistochemistry, a granular-
linear staining pattern could be visualized, which is typi-
cal for proteins close to or associated with the GBM. At
the ultrastructural level, it is further demonstrated by iEM
that CRIM1 is localized to the SD region of the podocyte
pedicles. This membrane-like structure spanning the gap
between the podocyte foot processes was demonstrated by
electronmicroscopyin1974[25].Foryears,theexactprop-
erties of the SD were only a subject for speculation; today
it has, however, been shown that the SD plays a pivotal role
in the permselectivity of the kidney.
The glomerular filtration barrier consists of fenestrated
endothelial cells, the glomerular basal membrane (GBM)
andtheSDofthepodocytes[26].Whereastheendothelium
andGBMimpartchargeselectivity,theGBMandespecially
the SD impart size and shape selectivity. The basis for the
permselectivity is the highly ordered net-like SD structure.
Current research is rapidly shedding light on the molecular
composition of the diaphragm, which has been shown to be
a zipper-like structure composed of seven major proteins,
the first of which to be discovered was nephrin, providing
the backbone of the structure [27]. The interest in the SD
has been spurred by the fact that genetic defects in one
of the core proteins results in the hallmark of renal dis-
ease, namely proteinuria [27–32]. A prototypical example
is the Finnish-type congenital nephrotic syndrome, where
the nephrin gene has been mutated, resulting in intrauterine
massive proteinuria [32].
In the adult human kidney, the tubular, interstitial
and vascular compartments, lacked CRIM1 expression as
judged by immunohistochemistry. This is at odds with the
results of Pennisi et al. who showed that in mice a strong
CRIM1 expression was seen in the afferent arteriole and
renal vasculature [4]. We addressed this discrepancy in
two ways. Commercially available antisera specified for
immunohistochemical detection of CRIM1 in humans are
scarce. We tested a rabbit antibody, obtained from Atlas
antibodies that gave a positive glomerular staining pattern.
We also obtained a chicken antibody developed for histol-
ogy, developed by the human proteome resource project
(www.hpr.se), obtaining an identical result. Furthermore,
we tested antisera from Santa Cruz and R & D systems
that,however,werespecifiedforwesternblottingpurposes.
Both of these gave negative results, also in human pla-
centa that was used as a positive control. Using Q-PCR,
we showed that the mRNA levels of CRIM1 were ∼10-fold
higher in podocytes as compared to renal cortical RNA.
We also included mRNA from primary human pulmonary
artery smooth muscle cells in order to assess if CRIM1
is indeed expressed in vascular smooth muscle. The re-
sults indirectly reconcile those of Pennisi et al. in that
mRNA levels similar to the podocyte levels were present
(Figure 3). The histological and PCR results may be in-
terpreted either as a species difference between man and
mouse regarding CRIM1 expression, or that the CRIM1
antigen is blocked from detection in human renal tis-
sue vasculature. Furthermore, the presence of CRIM1
mRNA in HPASMC indicates that CRIM1 has functions
during the growth and maintenance of vascular smooth
muscle.
In order to ultrastructurally determine the location of
CRIM1, iEM was performed demonstrating that the major-
ity of signal was localized to the podocytes, more specif-
ically to the filtration slit compartment. Some signal was
detected in the cytoplasm of the podocyte’s apical com-
partment. We interpret the cytoplasmic signal as CRIM1
being synthesized, or as being part of an intracellular pool
of CRIM1 retaining its ligands, as CRIM1 has been shown
to interact in an antagonistic way with BMP2, 4 and 7 in
the cytoplasmic compartment of COS-7 cells [2].
The actual function of CRIM1 in the adult podocyte re-
mains to be elucidated. The known CRIM1 ligands, BMP2,
4and7,areexpressedbythepodocytesduringnephrogene-
sis [33]. Homozygous knock-out of BMP2 and four results
in embryonic death during early gastrulation, while het-
erozygotes displaysevere genitourinary malformations and
hypoplastickidneys[34,35].Homozygousdisruptionofthe
BMP7 gene results in arrested renal development and peri-
natal death of the litter [36]. The phenotype of the BMP7-
deletedmiceparallelsthephenotypeseeninmicewherethe
wild-type CRIM1 has been replaced by a hypomorph ver-
sion [4,5]. With regard to the presence of BMP isoforms in
the adult kidney, the distribution of BMP7 has been shownCRIM1 in filtration slit of podocytes 2043
to be localized mainly to the distal tubules [18], although
another study showed the presence of BMP7 in the ma-
ture podocytes of the mouse glomerulus [37]. Of the other
two BMP ligands presently known to bind CRIM1, BMP2
has been shown to be downregulated in the adult kidney,
whereas the distribution of BMP4 is still unknown [17,38].
Since the picture is not entirely clear, the BMP expression
of adult glomerular cells requires further investigation. It
is possible that CRIM1 takes part in the release of BMP
for the localized paracrine interaction with the podocyte.
Sequestration of members of the TGF-β superfamily, such
as BMP 2, 4 and 7 to the vicinity of the SD, might implicate
that the integrity of the SD is dependent upon a localized
presence of these agents and that local fluctuations in con-
centration could be detrimental for the integrity of the SD.
VEGFA is a factor that podocytes express throughout life
[19,39]. Recently, CRIM1 has been shown to be involved
in the delivery of VEGFA to the glomerular endothelial
cells and furthermore, the localization of VEGFA as de-
termined by electron microscopy was shown to be quite
similar to the CRIM1 localization presented in the present
paper, indicating a possible site for interaction [5]. It has
also been demonstrated that anti-VEGF therapy and solu-
bleflt-1treatmentleadstofoot-processeffacement,nephrin
downregulationandglomerularendothelialdamage[40].In
a recent study, it was shown that podocytes regulate the ex-
pression of podocin and its interaction with CD2AP by an
autocrine VEGFA-dependent system [41]. These findings
imply another important function of CRIM1 as a mod-
ulator of VEGFA action, which if disturbed, also leads
to the common endpoint of foot process effacement and
proteinuria.
ItcouldalsobespeculatedthatonefunctionofCRIM1is
toactasasensorforthelevelsofitsagonists,conveyingthe
information to the segment of podocyte directly involved in
the insertion and maintenance of the SD. This function of
CRIM1 obviously requires an intracellular signal transduc-
tory apparatus, the existence of which is uninvestigated.
A third possibility for the strict compartmentalization of
CRIM1 to the SD could be a structural function of the
extracellular part of the protein, in some way interacting
with the slit membrane itself, adding to the structural
integrity of the SD. The seven major molecules of the SD
are all implicated in the structural integrity of the SD [27].
CRIM1, however, is not ascribed a structural function or
a function associated with the connection of the SD to
the actin cytoskeleton of the podocyte. The question is
how the podocyte brings about this compartmentalization
of the CRIM1 protein, since it is not known to interact
with the cytoskeleton. This might be possible by the action
of the lipid rafts that have been shown to be involved in the
functional organization of the SD [42]. By specialization of
themembranearoundtheSD,ameansfortheselectiveclus-
tering of membrane proteins is obtained, in turn, providing
a framework for various processes such as endocytosis,
cell adhesion and signal transduction events [43,44].
Summing up, we propose that CRIM1 may be added to
the list of proteins that make up the SD. Future studies
could be conducted using conditional knock-out of CRIM1
inpodocytesandalsobymoleculardissectingusingisolated
podocytes for in vitro studies.
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Glomerular filtration is normal in the absence of both agrin and
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Abstract
Background. For several decades, it has been thought that
the glomerular basement membrane (GBM) provides a
charge-selective barrier for glomerular filtration. However,
recent evidence has presented challenges to this concept:
selective removal of heparan sulfate (HS) moieties that im-
part a negative charge to the GBM causes little if any in-
crease in proteinuria. Removal of agrin, the major GBM
HS-proteoglycan (HSPG), from the GBM causes a pro-
found reduction in the glomerular anionic charge without
changing the excretion of a negatively charged tracer. Per-
lecanisanotherHSPGpresentintheGBM,aswellasinthe
mesangium and Bowman’s capsule, that could potentially
contribute to a charge barrier in the absence of agrin.
Methods. Here we studied the nature of the glomerular
filtration barrier to albumin in mice lacking the HS chains
of perlecan either alone or in combination with podocyte-
specific loss of agrin.
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